Aspire Biopharma Holdings (ASBP) Payables (2021 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Payables came in at $857925.0 in Q1 2026, down 67.54% year-on-year from $2.6 million in Q1 2025, and down 18.71% on a QoQ basis from $1.1 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Payables (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 6 years of Payables data on file, last reported at $857925.0 in Q1 2026.
- On a quarterly basis, Payables fell 67.54% year-over-year to $857925.0 in Q1 2026; TTM through Mar 2026 was $857925.0, a 67.54% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 14.23% from the prior year.
- Payables for Q1 2026 stood at $857925.0, down from $1.1 million in the prior quarter.
- Over the last five years, Payables for ASBP reached as high as $4.6 million in Q3 2025 and fell as low as $19067.0 in Q1 2022.
- Historically, Payables has averaged $935975.0 across 5 years, with a median of $284371.0 in 2023.
- Across the five-year window, Payables jumped 968.51% in 2023 and sank 67.54% in 2026, its largest moves.
- Year by year, Payables stood at $180634.0 in 2022, then decreased by 15.85% to $152005.0 in 2023, then jumped by 709.49% to $1.2 million in 2024, then decreased by 14.23% to $1.1 million in 2025, then dropped by 18.71% to $857925.0 in 2026.
- Per Business Quant data, the three most recent Payables figures were $857925.0 in Q1 2026, $1.1 million in Q4 2025, and $4.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | 10.62 Mn |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | 8.69 Mn |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 423.55 Mn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Aspire Biopharma Holdings | 1.10 Mn | -722,113.72 | 5,750.00 | 857,925.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 857,925.00 |
| Dec 31, 2025 | 1.06 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Jun 30, 2024 | 584,078.00 |
| Mar 31, 2024 | 365,010.00 |
| Dec 31, 2023 | 152,005.00 |
| Sep 30, 2023 | 104,379.00 |
| Jun 30, 2023 | 101,667.00 |
| Mar 31, 2023 | 203,732.00 |
| Dec 31, 2022 | 180,634.00 |
| Sep 30, 2022 | 96,016.00 |
| Jun 30, 2022 | 83,777.00 |
| Mar 31, 2022 | 19,067.00 |
| Dec 31, 2021 | 238,869.00 |